| MNSQX | VSCIX | MNSQX / VSCIX | |
| Total Expense Ratio | 0.76 | 0.03 | 2,533% |
| Annual Report Gross Expense Ratio | 0.76 | 0.03 | 2,533% |
| Fund Existence | 7 years | 29 years | - |
| Gain YTD | 16.794 | 14.591 | 115% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000000 | 5000000 | 20% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.58B | 189B | 1% |
| Annual Yield % from dividends | 0.38 | 1.23 | 31% |
| Returns for 1 year | 16.93 | 22.58 | 75% |
| Returns for 3 years | 30.27 | 43.44 | 70% |
| Returns for 5 years | 23.09 | 35.13 | 66% |
| Returns for 10 years | N/A | 156.07 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPQX | 20.02 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Premium C | |||
| CAVAX | 18.71 | 0.04 | +0.21% |
| SEI Catholic Values Equity F (SCVT) | |||
| GSIYX | 24.29 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps R6 | |||
| PIEQX | 22.30 | -0.17 | -0.76% |
| T. Rowe Price International Eq Index | |||
| RYOIX | 86.56 | -2.00 | -2.26% |
| Rydex Biotechnology Inv | |||